Grace Therapeutics (GRCE)

• Market cap: $54.3M
• 1 day: -6.65%
• 5 days: -4.62%
• 1 month: 3.54%
• 3 months: 10.03%
• 6 months: 15.84%
• Year to date: -4.1%
• 1 year: 1.74%
• 5 years: -89.47%
• 10 years: -95.62%
• Sector: Healthcare
• Industry: Biotechnology

About: Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Employees: 6